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Abstract 
Objective 
Investigate the associations of long-acting injectable (LAI) second generation antipsychotic drugs with 
number of relapses, psychiatric admissions, days hospitalized, intentional self-harm events, and costs linked 
to hospitalizations in incident patients diagnosed with schizophrenia. 
 
Method 
A nationwide, population-based, retrospective study utilizing mirror-image models  before and after 
initiation of LAI SGA. 
 
Results 
10,509 patients were included as study population, with analyses being conducted on 2,223 patients in a six-
month period, 1,383 in a 12-month period, 713 in a 24-month period. After initiation of LAI antipsychotics, 
patients experienced a reduction in number of relapses with an incidence rate ratio (IRR) of 0.60 for the first 
six months, IRR 0.64 for the first 12 months and IRR 0.64 for the first 24 months following initiation of LAI, all 
P<0.001. The number of psychiatric admissions was reduced in a similar manner with respective IRR of 0.59, 
0.60 and 0.64, all P<0.001. Psychiatric bed-days were reduced with 58, 100 and 164 days for the respective 
periods after LAI initiation, all P<0.001. In a Cox regression model in patients initiated on LAI, higher age at 
diagnosis, hazard rate ratio (HR) 0.99, 95%CI(0.98–0.99), P<0.001, and a later calendar year of diagnosis, HR 
0.99, 95%CI(0.98-1.00), P<0.05, were associated with a lower risk of relapse, whereas mainly psychiatric 
comorbidity, HR 1.07, 95% CI (1.04-1.11), P<0.001, and cardiovascular disease, HR 1.12, 95%CI(1.01-1.26), 
P<0.05, were associated with relapse. 
 
Conclusion 
Even though the design does not allow inferences regarding causality, these population-based findings 
support the use of second generation LAI antipsychotics. 
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1. Introduction 
In patients newly diagnosed with schizophrenia different trajectories of clinical course in terms of  
psychopathology, hospitalizations and response to treatment have been demonstrated to be associated with 
duration of untreated psychosis, age at onset, previous hospitalizations, socioeconomic status and  social and 
general function (Austin et al., 2015; Jäger et al., 2014; Levine and Rabinowitz, 2010). In general, patients 
newly diagnosed with schizophrenia respond well to antipsychotic drugs (Kahn et al., 2008), but based on 
the randomized clinical trials (RCTs) conducted in this population it has not been possible to elucidate a 
hierarchy of antipsychotic drugs regarding their effect (Zhu et al., 2017). Thus, the newest network meta-
analysis mainly guides treatment choices on side-effect profiles of the different available antipsychotic drugs 
and suggests for that reason to avoid haloperidol (Zhu et al., 2017). Despite of drug induced initial symptom 
reduction, and even remission in some patients with newly diagnosed schizophrenia, discontinuation rates 
are high, resulting in relapse and hospitalization (Kahn et al., 2008; Whale et al., 2016). It is still uncertain 
how to manage patients with newly diagnosed schizophrenia who do not respond to the initial treatment, 
but the currently ongoing OPTIMISE study, evaluating a stepped pharmacological treatment program with 
aggressive treatment for non-responders is expected to result in more clear guidelines for clinicians (Leucht 
et al., 2015). Early intervention studies in patients newly diagnosed with schizophrenia have in general shown 
a positive effect on symptoms, social function and risk of admission while patients were enrolled but effects 
have diminished over time when patients returned to standardized treatment (Albert et al., 2017; Chan et 
al., 2015; Norman et al., 2011). The lack of a sustained effect of these interventions, which in many cases is 
the result of a discontinuation of a successful or partially successful treatment with an oral antipsychotic has 
resulted in LAI antipsychotics being proposed as an early treatment option, to increase adherence to 
treatment and thereby hopefully to decrease the risk of relapse, hospitalization and deterioration of social 
function and quality of life (Correll et al., 2016; Stahl, 2014). With the emergence of several second 
generation antipsychotic drugs as LAI, the treatment armamentarium has not only expanded but also 
improved, because the side effect profiles of the second generation antipsychotic LAI are more favorable 
than those of the first generation antipsychotic LAI (Correll et al., 2016). Also, the different side effect profiles 
within the group of second generation antipsychotic LAI provide clinicians with the possibility of letting 
treatment choice be guided by side-effects profiles combined with individual patient tolerability (Correll et 
al., 2016).  
In the current study, we wished to investigate if a change from oral antipsychotic treatment to LAI second 
generation antipsychotic drugs was associated with changes in number of relapses, number of admissions, 
use of bed days, occurrence of intentional self-harm and treatment cost, utilizing a mirror-image design in a 
nationwide population. We also wished to identify explanatory variables associated with relapse in patients 
treated with LAI second generation antipsychotics utilizing a Cox regression model. 
2. Materials and methods 
2.1. Registers used 
Data on psychiatric contacts and psychiatric disorders were retrieved from the Danish Psychiatric Central 
Research Register (DPCRR) (Mors et al., 2011). Data on hospital contacts and somatic diseases were retrieved 
from the Danish National Patient Register (NPR)(Lynge et al., 2011). Data on prescription of medication were 
retrieved from the Danish National Prescription Registry (DNPR) with data available from 1995 and onwards 
(Gaist et al., 1997).  
All register data are linked to each individual patient via the unique personal identification number (CPR) 
assigned to all residents at birth or upon immigration (Munk-Jorgensen and Ostergaard, 2011). 
Data are not accessable to the public, and access is only provided upon approval from The Danish Data 
Protection Agency and the Danish Health Authority and Statistics Denmark. 
 
2.2 . Design 
A nationwide, population-based, retrospective study. 
 
2.3. Population 
Patients diagnosed with schizophrenia (ICD-10 F20.x) for the first time between January 1st 1996 and 
December 31st 2013, who had been prescribed a LAI second generation antipsychotic (Anatomical 
Therapeutic Chemical Classification System (ATC) codes N05AX12 (aripiprazole), N05AH03 (olanzapine), 
N05AX13 (paliperidone) or N05AX08 (risperidone), i.e. second generation antipsychotic LAI available in 
Denmark in the study period) were identified. Patients diagnosed with schizophrenia (ICD-8 300 or ICD-10 
F20.x) before January 1st 1996 were excluded, as well as patients treated with second generation 
antipsychotic LAI before the schizophrenia diagnosis was registered. Thereby constructing a cohort of 
incident patients diagnosed with schizophrenia followed until initial treatment with a second generation 
antipsychotic LAI. 
From 2008 onwards all incident patients diagnosed with schizophrenia had antipsychotic drugs dispensed 
free of charge through hospital pharmacies during the first two years of treatment implying that no 
prescriptions were registered during these two years. To ascertain if patients were exposed to the shortest 
mirror image period (six months) a lag time of two years plus half a year of mirror image period was needed, 
resulting in all patients from January 1st 2008 until December 31st 2013 being included with 913 days of 
delay from diagnosis.  
 
2.4. Outcome measures 
2.4.1. Number of relapses 
Relapse was defined as either hospitalisation in a psychiatric ward or hospital contact in a somatic/psychiatric 
ward due to intentional self-harm (ICD-10 X64-X80). Number of relapses were the sum of occurrences of 
these events. 
 
2.4.2. Number of psychiatric hospital admissions 
Defined as number of admissions to a psychiatric ward regardless of diagnosis. 
 
2.4.3. Number of psychiatric in-hospital bed days  
Defined as number of bed days in connection with a hospitalisation in a psychiatric ward in patients admitted. 
 
2.4.4. Intentional self-harm 
Defined as number of hospital contacts to a somatic/psychiatric ward due to intentional self-harm (ICD-10 
X64-X80). 
 
2.4.5. Hospital costs  
Defined as the sum of Danish standard hospitalisation tariffs for all hospital contacts for all admissions per 
day hospitalized and for all outpatient contacts for each defined mirror image period 
(Sundhedsdatastyrelsen, n.d.). 
 
2.5. Statistical analysis 
The primary analysis was a mirror-image analysis of number of events defined under outcome measures in 
mirror image periods of 6, 12, and 24 months. The index of the mirror was defined as initiation of LAI. The 
retrospective and prospective window was defined as of equal length in each participant, and consisted of 
periods of 6, 12, and 24 months retrospectively and prospectively. Patients were included in all periods for 
which they could deliver full observation time on treatment, e.g. a patient could be included in several mirror 
windows, but only if they continued LAI throughout each of the observation periods. 
We employed linear regression for the outcomes; psychiatric in-hospital bed-days and hospital costs, while 
we used Poisson regression for relapse, psychiatric hospital admissions and intentional self-harm to calculate 
differences between mirror-image periods. Patients who died, ended LAI treatment or immigrated before 
the end of study were excluded at that time point.  
In addition, we calculated mean values, including confidence intervals, of all outcomes before and after index, 
respectively. 
Sensitivity analyses on effects of missing data on medication during hospitalisations were defined a priori 
comparing admitted to non-admitted patients, as well as imputing data during hospitalisation from data on 
LAI antipsychotic drug use before and after hospitalisation.  
Furthermore, sensitivity analyses comparing patients diagnosed before and during the freely dispensed 
antipsychotic drugs were also conducted as defined a priori. 
 
Secondly, we defined a Cox regression model with relapse defined as event, and entry defined as initiation 
of LAI. The model included severity of primary psychiatric disorder, psychiatric co-morbidity (see below), 
somatic co-morbidity (see below), as well as age, gender, and year of diagnosis as defined below. Patients 
were followed until event, end of LAI treatment, death or end of study (whichever came first).  
 
We defined a post-hoc Cox regression model including the same explanatory variables, except for the 
psychiatric co-morbidity score, which instead was added with each component of co-morbidity (see below) 
as explanatory variables, as a sensitivity analysis, to evaluate the effects of each psychiatric co-morbidity. 
 
P-values < 0.05 were considered statistically significant.  
 
Statistical analyses were performed with STATA 13 at the Statistics Denmark server with remote access 
(College Station, 2009). 
 
2.6. Explanatory variables for the Cox regression analysis 
2.6.1. Severity of primary psychiatric disorder 
The current Danish registers do not include data on severity. Therefore, we used the following variables as 
proxy markers of disease severity: number of psychiatric admissions, number of psychiatric bed days and 
number of psychiatric outpatient contacts after incident diagnosis but before LAI initiation for all variables.  
 
2.7. Psychiatric co-morbid disorder 
We defined a psychiatric co-morbidity score by a diagnosis in one or more of the following groups: psychosis 
(ICD-10 F2x.x), affective disorders (ICD-10 ICD 3x.x), substance misuse (ICD-10 F1x.x), other psychiatric 
diagnosis (remaining ICD-10 Fx.x diagnosis), and intentional self-harm (ICD-10 X64.x to F80.x), with each 
group resulting in a single point increase on a sum score. 
 
2.8. Somatic co-morbidity 
Known somatic disease is a risk factor for additional somatic disease and subsequent hospitalisations, why 
the presence of cardiovascular diseases (ICD-10 I05.x-I15.x, I20.x-I28.x, I30.x-I52.x, I60.x-I89.x, I95.x-I99.x), 
diabetes (ICD-10 E10 – E14), chronic obstructive pulmonary disease (ICD-10 J44.x) and hepatitis (ICD-10 B15.x 
– B19.x), were included as explanatory variables. 
 
3. Results 
In the current study we included 10,509 patients (6,358 males and 4,151 females) followed for 5,931 person-
years (males 3,869 person-years and females 2,062 person-years), with further demographics described in 
table 1. Considering the whole study period, not adjusting for duration of follow-up, participants had a mean 
of 3.03, 95% CI (2.91 – 3.15) psychiatric admissions before initiation of a second generation antipsychotic LAI 
(SGA LAI), and a mean of 1.04, 95%CI (0.95 – 1.13) admissions after initiation of SGA LAI. Likewise, before 
initiation of SGA LAI participants had a mean of 183.74, 95% CI (177.35 – 190.14) psychiatric bed days as 
compared to 25.36, 95%CI (23.56 – 27.17) after initiation of SGA LAI. Mean hospital costs before initiation of 
SGA LAI were 432.16, 95% CI (414.40 – 449.91) thousand Danish kroner per patients, as compared to 76.74, 
95% CI (71.38 – 82.11) thousand Danish kroner per patient after initiation of SGA LAI. Adjusting for duration 
of follow-up, the mirror-image analysis with pre- and post-LAI study periods of 6, 12 and 24 months showed 
a reduction of 35-40 percent in number of relapses for all mirror-image periods after SGA LAI initiation, a 
reduction of 35-40 percent in number of psychiatric admission for all mirror-image periods after SGA LAI 
initiation,  a reduction of 85 percent in number of days hospitalized in all mirror-image periods after SGA LAI 
initiation, and a reduction of 75-80 percent in hospital costs, as shown in table 2. We furthermore conducted 
frequency analyses of number of relapses, psychiatric admissions and psychiatric bed days showing a left 
shift in frequencies, more patients with a lower number of the specified outcome, after initiation of LAI as 
compared to before, as shown in figure 1. The results from the mirror-image sensitivity analyses described 
in the Materials and Methods section showed similar results (data not shown). 
 
Secondly, the analysis of variables associated with relapse risk in patients after initiation of LAI  showed that 
especially psychiatric co-morbidity (Hazard rate ratio (HR) 1.07, 95%CI (1.04 – 1.11), P < 0.001) and a diagnosis 
of cardiovascular disease (HR 1.12, 95% CI (1.01 – 1.26), P < 0.001) increased the risk of relapse in patients 
initiated on a LAI ( see table 3, also displaying the effects of the remaining explanatory variables).  
The increased HR for the psychiatric co-morbidity score resulted in a sensitivity analyses investigating all 
components included in the psychiatric co-morbidity score as explanatory variables in a post-hoc defined Cox 
regression model showing that a diagnosis of an affective disorder (HR 1.13, 95% CI (1.05 – 1.23), P < 0.005), 
as well as a diagnosis of a substance misuse disorder (HR 1.11, 95% CI (1.03 – 1.19), P < 0.01)) was associated 
with relapse in patients initiated on LAI (table 4). 
 
No new safety signals were discovered in this research which was in line with the expectations given the 
method and data sources used. 
 
4. Discussion 
In the current study, we showed that patients initiating second generation antipsychotic LAIs had a time 
adjusted reduction in the number of relapses of approximately 35-40 percent with a similar reduction in 
number of admissions to psychiatric hospital as compared to the period before initiating the treatment. 
Likewise, in hospitalized patients, the number of days hospitalized was reduced with 85 percent. As a 
consequence, the costs associated with hospital-based psychiatric treatment of patients decreased to 
approximately one quarter in the periods investigated after initiation of second generation antipsychotic LAI 
as compared to periods before initiation. 
In the Cox regression model we showed that in patients initiated on LAI, age at diagnosis and a later calendar 
year of diagnosis were associated with a lower risk of relapse, whereas a higher number of previous 
admissions, a higher number of previous psychiatric bed days and a higher number of previous outpatient 
contacts, as well as psychiatric comorbidity and a diagnosis of cardiovascular disease were associated with 
an increased risk of relapse. The post-hoc defined Cox regression model applied to the same population 
including all components from the psychiatric comorbidity score showed similar results as the initial model, 
but additionally that a diagnosis of an affective disorder as well as a substance misuse diagnosis resulted in 
an increased risk of relapse. 
Previous RCTs comparing LAIs antipsychotics to oral antipsychotic drugs have failed to show any significant 
difference between the two formulations on proxy markers of relapse or time to all-cause discontinuation 
(Kishimoto et al., 2014), contrasting the current findings of a reduction on all outcome measures, except from 
intentional self-harm. The main reasons for similar outcomes in LAI and oral antipsychotic drug treated 
patients in RCTs are most likely a consequence of the RCTs themselves. In RCTs adherence to medication is 
optimized by e.g. frequent clinical assessments and by excluding patients who have somatic co-morbidity, 
psychiatric comorbidity like substance misuse or are otherwise unstable (Alphs et al., 2014). These 
characteristics were all linked to relapse in the current study and they are most likely also linked to a reduced 
adherence to treatment (Alphs et al., 2014; Nordon et al., 2017). Furthermore, in contrast to RCTs, 
observational studies like mirror-image studies, in which LAI is chosen by the clinician on the basis of patient´s 
behavior like non-adherence, have shown a significant reduction in relapse (Kishimoto et al., 2013). Such 
studies generally do not use rating scale determined proxy markers of relapse, but instead use objective 
measures like number of hospitalizations which are more relevant to clinicians (Alphs et al., 2014). The results 
from the current study showing a reduction in number of hospitalizations of approximately 0.57 is in line with 
a meta-analysis from Kishimoto et al (Kishimoto et al., 2013) based on 25 mirror-image studies, which showed 
a reduction in number of hospitalizations of 0.38. A recent small study by Vincent et al (Vincent et al., 2017) 
investigating paliperidone palmitate showed a reduction  in admissions to approximately one third after LAI 
initiation, but with no difference in days hospitalized. Similarly Mesones-Peral et al (Mesones-Peral et al., 
2017) also recently found reductions in admissions and bed days associated with paliperidone palmitate . 
Lastly, Souaiby et al (Souaiby et al., 2017) investigated the effects of combining LAIs to clozapine treatment 
in patients diagnosed with schizophrenia or schizoaffective disorder showing a reduction in admissions of 
approximately 60 percent and a reduction in bed days of approximately 83 percent in the year following LAI 
initiation. Combined, the three latest studies and the meta-analysis, included less patients than the current 
study, which by including a nationwide study population adds to the generalizability to clinical practice of the 
overall findings  (Kukull and Ganguli, 2012). A newly published nationwide study utilizing a Cox regression 
model also showed similar results with HR for relapse of approximately 0.25 in incident patients diagnosed 
with schizophrenia treated with both first and second generation antipsychotic LAI as compared to remaining 
patients, albeit results not directly comparable due to the differences in methodology (Taipale et al., 2017). 
In patients treated with LAIs, non-compliance and discontinuation of treatment has often been an indication 
for LAI treatment (Kishimoto et al., 2013). The study by Attard et al showed a high first year continuation of 
LAI after initiation (Attard et al., 2014). In the current study, we did not specifically investigate the attrition 
rate, but showed that the 2,233 patients being treated for the first six months was reduced to 1,383 patients 
treated for 12 months and 713 treated for 24 months, which could be caused by lack of retro- or prospective 
follow-up or discontinuation of treatment. 
If ingested, an oral antipsychotic drug has the same or a similar active component as the corresponding LAI, 
with the differences being due to different pharmacokinetic properties, resulting in a slow and constant 
release of the active compound over several weeks and, consequently, a more stable plasma concentration 
in LAI treated patients. However, in RCTs a stable plasma concentration per se has not been demonstrated 
to be associated with significantly better efficacy or less side effects as compared to a less stable plasma 
concentration (Kishimoto et al., 2014; Ostuzzi et al., 2017). The potential benefit of treatment delivered by 
LAI in contrast to oral antipsychotic agents therefore most likely lies in the removal of daily adherence issues, 
and in clinicians potentially being made aware early if patients do not receive treatment, resulting in a 
potentially diminished risk of relapse as compared to oral treatment in which patients can be intermittently 
non-adherent without this is detected by the clinician resulting in an increased risk of relapse (Bossie et al., 
2015). Additionally, even though a LAI is discontinued for longer periods of time, an emergent relapse will be 
substantially delayed as compared to the situation where an oral agent is discontinued.   
As to our findings that a diagnosis of a co-morbid affective disorder, a co-morbid substance misuse disorder, 
or a diagnosis of a cardiovascular disease was associated with an increased risk of relapse, substance misuse 
has previously been linked to an increased risk of relapse (Porcelli et al., 2016). In RCTs, co-morbid psychiatric 
disorders are often an exclusion criterion, and in observational studies affective disorders co-morbid to 
schizophrenia have not been linked with relapse as an outcome previously (Bowtell et al., 2017; Porcelli et 
al., 2016). The finding of an association between relapse and cardiovascular disease is novel, and to further 
elucidate this, studies with other designs could be conducted. 
When the potential reduced costs associated with LAI treatment utilizing standardized mean costs per bed 
day in a Danish psychiatric hospital were calculated, a clear reduction in costs due to a reduction in days 
hospitalized could be demonstrated. In the current study we did not include costs for outpatient contacts, 
contacts to general practitioners, costs associated with treatment of physical diseases or cost of antipsychotic 
drug treatments. Previous studies have shown that the main direct cost associated with treatment of 
schizophrenia is hospitalizations, closely followed by antipsychotic drug treatment and several types of 
outpatient treatment components (Knapp et al., n.d.; Zhu et al., 2008). The indirect costs associated with 
schizophrenia are harder to determine and consists of many components including unemployment, reduced 
productivity if employed, caregivers and family having a reduced productivity and premature mortality 
(Knapp et al., n.d.; Rosenberg, n.d.). Most other studies have calculated the economic effects of prescribing 
second generation LAIs, which most often are more expensive than the similar oral treatment option, in 
conjunction with the reduced costs of hospitalization, showing a positive economic effect of LAI treatment 
(Correll et al., 2016). Contrary to previous studies which have mainly had a short follow-up period, and a 
general short study period, we chose to include patients over an 18-year period with up to a total of four-
year mirror period. Over this time-period, it would be difficult to calculate the specific costs associated with 
antipsychotic treatment as prices would vary and no formal register thereof exists. As a result we have chosen 
only to incorporate a simple economic calculation based on direct costs associated with hospitalizations.   
Aripiprazole LAI was marketed in Denmark from late 2013 and paliperidone palmitate LAI three months, i.e.  
after the study period, therefore no patients were exposed to these drugs in the current study. 
4.1. Strengths and limitations 
The mirror image model primarily used in this study does carry some methodological weaknesses, for which 
it is not possible to adjust. The initiation of a LAI antipsychotic drug is not a random event, and is most often 
initiated at a certain time-point due to a specific cause, e.g. low adherence to treatment, multiple relapses 
and hospitalizations, substance misuse, intentional self-harm, which all would bias result towards better 
outcomes after LAI initiation, due to regression towards the mean of number of relapses, number of 
hospitalizations, and number of bed days in the period after LAI initiation. This bias will be most profound for 
the time immediately before and after LAI initiation, and the effect would most likely diminish over time, 
making the results of the longer mirror-image periods less sensitive to this bias. Similar to this would be a 
specific expectation bias, since patient, relatives, and clinician would expect an improvement to occur after 
LAI initiation, which could cause a delayed referral or treatment seeking of patients towards psychiatric 
treatment. However, a reduced use of hospitalization and help seeking immediately after initiation of LAI 
would be expected, so again, most likely this would not affect the results from the longer mirror-image 
windows. Contrary to this, the use of an LAI would result in an immediate warning being given to the clinician 
if a patient was non-adherent to an LAI in contrast to oral treatment, which would result in a bias towards 
admission and hospitalization, biasing our results in a conservative manner. From a pure methodological view 
point, the main strength of the mirror-image design is the elimination of genetic, personality, and other stable 
characteristics for each patient biasing results, which would have occurred in a case-control design. The main 
weakness, general for all observational studies, is that no causal inferences can be made. 
The 913 days of delay in patients diagnosed in the period 2008 and onwards could result in differences 
between patients diagnosed early in the study period as compared to later, but the sensitivity analysis did 
not show any significant effects on outcomes. 
In conclusion, our findings show a reduction in number of relapses, number of admissions, days hospitalized 
if admitted, and as a result lowered costs after LAI initiation. These findings are similar to those of previous 
smaller studies conducted over shorter time periods investigating prevalent cases diagnosed with 
schizophrenia initiating LAI. Contrary to the previous studies we used a nation-wide population of newly 
diagnosed patients increasing generalizability by including all diagnosed patients and by including patients 
over an 18-years period.  These population-based findings strongly support the use of LAI second generation 
antipsychotics in patients newly diagnosed with schizophrenia, although the design does not allow causal 
inferences.  
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Demographics Total Male Female 
Mean age at diagnosis ±SD (years) 33.61 12.70 32.22 11.49 35.72 14.10 
Mean age at LAI  ±SD (years) 36.58 13.34 35.15 12.12 38.75 14.74 
Mean psychiatric comorbidity score (95%CI) 2.34 (2.33-2.36) 2.31 (2.28-2.31) 2.40 (2.37-2.43) 
             
Long acting injectable n (%) n (%) n (%) 
Olanzapine 5455 (52%) 3508 (55%) 1947 (47%) 
Risperidone 4580 (44%) 2578 (41%) 2002 (48%) 
Paliperidone 474 (5%) 272 (4%) 202 (5%) 
Aripiprazole - - - - - - 
              
 
Table 1: Demographics of study population
 6 month mirror-image analysis (N = 2233) 
  Mean before 95% CI Mean after 95% CI Adj.Effect. P 
Variable              
# relapse 1.08 
1.01 1.14 0.64 0.58 0.71 
0.60 (IRR) < 0.001 
# psychiatric admissions 0.82 
0.76 0.87 0.48 0.42 0.54 
0.59 (IRR) < 0.001 
# psychiatric bed days 68.40 
65.45 71.36 10.37 9.14 11.59 
-58.04 < 0.001 
# intentional self-harm contacts 0.04 
0.03 0.06 0.04 0.02 0.06 
0.92 (IRR) 0.67 
Hospital costs (in 1,000 Danish kroner) 145.32 
136.11 154.52 33.40 30.15 36.65 
-111.92 < 0.001 
               
 12 month mirror-image analysis (N = 1383) 
  Mean before 95% CI Mean after 95% CI Adj.Effect. P 
Variable              
# relapse 
1.69 1.56 1.82 1.09 0.93 1.24 
0.64 (IRR) < 0.001 
# psychiatric admissions 
1.37 1.26 1.49 0.83 0.70 0.96 
0.60 (IRR) < 0.001 
# psychiatric bed days 
118.49 111.48 125.49 18.82 16.15 21.49 
-99.67 < 0.001 
# intentional self-harm contacts 
0.08 0.05 0.11 0.06 0.03 0.10 
0.80 (IRR) 0.41 
Hospital costs (in 1,000 Danish kroner) 
261.51 240.34 282.68 62.82 55.24 70.40 
-198.69 < 0.001 
               
 24 month mirror-image analysis (N = 713) 
  Mean before 95% CI Mean after 95% CI Adj.Effect. P 
Variable              
# relapse 
2.68 2.40 2.96 1.72 1.42 2.01 
0.64 (IRR) < 0.001 
# psychiatric admissions 
2.16 1.93 2.39 1.37 1.03 1.72 
0.64 (IRR) < 0.001 
# psychiatric bed days 
195.88 178.70 213.05 32.26 26.11 38.42 
-163.62 < 0.001 
# intentional self-harm contacts 
0.13 0.06 0.19 0.12 0.04 0.20 
0.93 (IRR) 0.81 
Hospital costs (in 1,000 Danish kroner) 
471.59 418.95 524.23 113.99 95.85 132.13 
-357.60 < 0.001 
              
 
  
 
 
Table 2: Mirror image analysis with 6, 12 and 24 months of pre- and post-LAI initiation study period. The 
effect size is represented by the coefficient of a linear regression analysis unless otherwise specified. IRR: 
Incidence rate ratio.
  HR 95%CI P 
Age at diagnosis 0.99 0.98 0.99 < 0.001 
Sex 1.04 0.97 1.12 0.281 
Calendar year of diagnosis 0.99 0.98 1.00 < 0.05 
# of psychiatric admissions 1.02 1.01 1.02 < 0.001 
# of psychiatric bed days 1.00 1.00 1.00 < 0.05 
# of outpatient contacts 1.00 1.00 1.00 < 0.001 
Psychiatric comorbidity score 1.07 1.04 1.11 < 0.001 
Diagnosis of cardiovascular disease 1.12 1.01 1.26 < 0.05 
Diagnosis of diabetes 0.87 0.70 1.09 0.235 
Diagnosis of COPD 0.88 0.60 1.28 0.495 
Diagnosis of hepatitis 1.27 0.91 1.78 0.162 
 
 
Table 3: Cox regression model with relapse as outcome. HR: Hazard rate ratio. CI: Confidence interval. #: 
number of. COPD: Chronic obstructive pulmonary disease.
  HR 95%CI P 
Age at diagnosis 0.99 0.98 0.99 < 0.001 
Sex 1.05 0.97 1.13 0.281 
Calendar year of diagnosis 0.99 0.98 1.00 < 0.05 
# of psychiatric admissions 1.02 1.01 1.02 < 0.001 
# of psychiatric bed days 1.00 1.00 1.00 < 0.05 
# of outpatient contacts 1.00 1.00 1.00 < 0.001 
Psyciatric comorbidity HR 95%CI P 
Diagnosis of psychosis omitted       
Diagnosis of affective disorder 1.13 1.05 1.23 < 0.005 
Diagnosis of substance misuse 1.11 1.03 1.19 < 0.01 
Other psychiatric diagnosis 1.03 0.96 1.11 0.431 
Diagnosis of intentional self-harm 0.98 0.86 1.12 0.798 
Somatic comorbidity HR 95%CI P 
Diagnosis of cardiovascular disease 1.12 1.01 1.26 < 0.05 
Diagnosis of diabetes 0.85 0.68 1.06 0.148 
Diagnosis of COPD 0.88 0.60 1.28 0.495 
Diagnosis of hepatitis 1.27 0.91 1.78 0.162 
 
 
Table 4: Post-hoc defined Cox regression model with relapse as outcome. HR: Hazard rate ratio. CI: 
Confidence interval. #: number of. COPD: Chronic obstructive pulmonary disease. 
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 Figure 1: Frequencies of relapse, psychiatric admissions and psychiatric bed days before (left side) and after (right side) initiation of long action injectable 
antipsychotics
